Week In Review: Beijing BoomRay Closes $43 Million A Round For Novel Radionuclide Drugs
September 10, 2022 at 15:40 PM EDT
Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment.
